HCV and Liver Cancer

Liver Cancer pic

Liver Cancer
Image: WebMD.com

Robert Hindes, MD, is the Chief Medical Officer of Trek Therapeutics, a company with a mission to develop effective and safe treatments for the hepatitis C virus (HCV) and deliver them to patients at affordable rates. Prior to co-founding Trek, Robert Hindes, MD, was in charge of the clinical development program at Pharmasset, a company purchased by Gilead Sciences in 2012.

HCV often spreads through blood-to-blood contact, such as through transfusions, the shared use of unsterilized needles, or the use of poorly sanitized medical equipment. Fortunately, it is possible to treat HCV with a combination of drugs, and newly approved drug regimens have achieved a greater than 90 percent cure rate. All forms of hepatitis attack the liver, but HCV is of particular concern since most infected individuals develop chronic infection. Left untreated, it may cause cirrhosis, hepatic failure, and liver cancer. HCV affects an estimated 130 million to 150 million people worldwide, and according to the World Health Organization, approximately 500,000 HCV-related deaths occur every year.


Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s